JNJ - Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK | Benzinga
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have reached an agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson company (NYSE: JNJ), to transfer exclusive worldwide rights to further develop and commercialize JNJ-3989 to GSK.
JNJ-3989 (formerly ARO-HBV) was initially in-licensed by Janssen from Arrowhead in 2018.
JNJ-3989 is an investigational hepatitis B virus-targeted small interfering ribonucleic acid (siRNA) therapeutic that GSK intends to evaluate in a sequential regimen with bepirovirsen, GSK’s investigational antisense oligonucleotide, for non-cirrhotic patients with chronic hepatitis B (CHB) ...